Gastro-oesophageal acid-related disease,co-morbidity and medical care cost

Abstract

Objective: To analyse the incremental medical care cost of gastro-oesophageal acid-related disease (GERD), and its interactive effects with other diagnoses.

Methods: A retrospective cohort study was conducted. Six hundred GERD patients were randomly selected and 600 non-GERD patients were selected, matched by age, gender, prescription pharmaceutical benefits and insurance status. Information on demographics, direct medical care cost (DMC) (inpatient, ambulatory and pharmaceuticals) and health service utilization was obtained from a large, not-for-profit managed-care organization across 3 years (1996—1998). DMCs were compared between GERD and non-GERD groups using the bootstrap method. Random coefficient log linear regression models were used to analyse incremental cost and assess its association with other diagnoses.

Results: The mean annual DMC for the GERD group was $4906, as compared to $2054 for the non-GERD group. The increase in the DMC in the GERD group was attributable to increased co-morbidity. Age and gender had no effect on total cost for the GERD population. Among costs of services, the GERD group had a 2.00-fold higher cost associated with outpatient services, a 1.70-fold higher cost associated with inpatient services, and a 2.70-fold higher cost associated with pharmacy.

Conclusions: GERD is a chronic disease often associated with other diagnoses that significantly affect total DMC. Although the direct cost of treating GERD is low, patients with GERD had significantly higher total medical care cost than those without GERD. The addition of one more disease to a person's existing group of diseases has an important long-term health cost impact.

Keywords

Direct medical care cost GERD Incremental cost Inpatient cost Outpatient cost

Get full access to this article

View all access options for this article.

References

Shaheen NJ , Hansen RA , Morgan LM , et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128-38.

Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. Am J Gastroenterol 2001; 96: S16-21.

Jones R. , Galmiche JP Review: what do we mean by GERD? Definition and diagnosis. Aliment Pharmacol Therap 2005; 22(Suppl. 1): 2-10.

Johanson JF Critical review of the epidemiology of gastroesophageal reflux disease with specific comparisons to asthma and breast cancer. Am J Gastroenterol 2001; 96: S19-21.

Keyser MS , Crawley JA , Goldberg GA , Shaw MM Gastroesophageal reflux disease in a managed care setting: charges by place and type of service. J Managed Care Pharmacy 1998; 3: 336-43.

Lair TJ , Anderson DR , Crawley JA Utilisation and expenditures in the treatment of patients with gastro-intestinal reflux disease. Pharmaco Econ 1998; 15: 325-36.

Sandler RS , Everhart JE , Donowitz M. , et al. The burden of selected digestive diseases in the United States . Gastroenterology 2002; 122: 1500-11.

Stålhammar N-O. , Carlsson J. , Müller-Lissner S. , et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmaco Econ 1999; 16: 483-97.

Willich SN , Nocon M. , Kulig M. , et al. Cost-of disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Therap 2006; 23: 371-6.

10.

Bjorkman DJ Community issues in gastroespohageal reflux disease: what we know and what we do not know. Am J Gastroenterol 2001; 96: s34-43.

11.

Fendrick MA Management of patients with symptomatic gastroesophageal reflux disease: a primary care perspective. Am J Gastroenterol 2001; 96: s29-37.

12.

Levin TR , Schmittdiel JA , Kunz K. , et al. Costs of acid-related disorders to a health maintenance organization . Am J Med 1997; 103: 520-8.

13.

Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: s46-53.

14.

Mason J. , Hungin APS. Review article: gastro-oesophageal refux disease - the health economic implications . Aliment Pharmacol Therap 2005 ; 22(Suppl. 1): 20-31.

15.

Wahlqvist P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol 2001; 96: s57-60.

16.

DeVault RK , Castell DO , Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines - updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-42.

17.

Charlson ME , Pompei P. , Ales KL , et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.

18.

Deyo RA , Cerkin DC , Ciol MA Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-19.

19.

Klabunde CN , Warren JL , Legler JM Assessing comorbidity using claims data - an overview. Medical Care 2002; 40(Suppl.): IV-26-IV-35.

20.

Ross LL , Stranc L. , James RC , et al. Complications, comorbidities and mortality: improving classification and prediction. Health Service Res 1997; 32: 229-38.

21.

Romano PS , Ross LL , Jollis J. Adapting a clinical comorbidity index for use with ICD-9 cm administrative data. J Clin Epidemiol 1994; 46: 1075-9.

22.

Jones AM Health econometrics. In: Culyer AJ , Newhouse JP , eds. Handbook of health economics Vol. 1A, New York: North-Holland Elsevier, 2000: 265-344.

23.

Zhou X.-H. , Gao S. , Hui SL Methods for comparing the means of two independent log-normal samples . Biometrics 1997; 53: 1129-35.

24.

Diem JE , Liukkonen JR A comparative study of three methods for analyzing longitudinal pulmonary function data. Statistics Med 1988; 7: 19-28.

25.

Greene WH Econometric analysis, 4th edn. Upper Saddle River, NJ: Prentice Hall, 2000.

26.

Sayrs LW Pooled time series analysis. Newbury Park: Sage Publications, The International Professional Publishers, 1998.

27.

Duan N. Smearing estimate: a nonparametric retransformation method. J Am Statistical Assoc 1983; 78: 605-10.

28.

Manning WG The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Economics 1998; 17: 283-95.

29.

Bloom BS , Jayadevappa R. , Wahl P. , Cacciamanni. Time trends in cost of caring for people with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: s64-9.

30.

Joish VN , Donaldson G. , Stockdale W. , et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Current Med Res Opin 2005; 21: 535-44.

31.

Leodolter A. , Nocon M. , Kulig M. , et al. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study . World J Gastroenterol 2005; 11: 148-51.

32.

Brook RA , Wahlqvist P. , Kleinman NL , et al. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Therap 2007; 26: 889-98.

33.

Diehr P. , Yanez D. , Ash A. , et al. Methods for analyzing health care utilization costs. Annu Rev Public Health 1999; 20: 125-44.